



Hoofddorp, the Netherlands
November 14, 2018

Dear Shareholder,

On behalf of IGEA Pharma N.V. (the "**Company**"), it is a pleasure to invite you to attend the Extraordinary General Meeting on **Thursday November 29, 2018** (the "**EGM**"). The meeting will be held at the offices of De Brauw Blackstone Westbroek N.V., Claude Debussylaan 80, 1082 MD, Amsterdam, the Netherlands. The meeting will start at **10.00 CET**.

The Company intends to have all of its issued and outstanding shares listed in accordance with the International Reporting Standard of SIX Swiss Exchange Ltd (the "**Listing**"). The main purpose of the EGM is to adopt a balance sheet evidencing sufficient equity to allow for the repurchase of the Company's shares following the Listing.

The topics to be discussed at the EGM are set out in the agenda together with the explanatory notes to the agenda. You can find the agenda and other related documents and further information regarding registration and voting by proxy on our website at www.igeapharma.nl. Copies of the meeting documents are available to shareholders via Van Lanschot N.V. ("**Van Lanschot**"), either by e-mail to proxylvoting@kempen.nl or by telefax +31 20 348 9549. These documents are also available for shareholders at the Company's offices, Siriusdreef 17, 2132 WT Hoofddorp, the Netherlands.

Record Date

You are entitled to participate in and vote at the EGM if you, after all changes have been processed, have these rights on Thursday November 1, 2018 at 6:00 pm (CET) (the "**Record Date**") and are registered as such in one of the registers designated by the Company's Management Board, provided that you have registered for the EGM in accordance with the provisions set forth below.

Meeting attendance

If you wish to attend the EGM either in person including by means of a conference call or video conference or by proxy, we kindly request you to notify Van Lanschot through your bank or stockbroker. Notification can take place as of today, but no later than November 22, 2018 6:00 pm CET. All attendees must be prepared to show a valid proof of identity or in case of attendance via conference call or video conference to answer questions for identification purposes.

Voting by proxy

If you choose to be represented at the EGM or to attend the EGM by means of a conference call or video conference, in addition to registering for the EGM as described above, you are requested to send a signed proxy instrument separately to cast your votes. The duly signed proxy instrument needs to be received by no later than November 22, 2018 6:00 pm CET at the following address:

IGEA Pharma N.V.
Attn. Diego Mortillaro

Siriusdreef 17
2132 WT Hoofddorp
The Netherlands
Email: mortillaro@igearesearch.com

With a copy to Van Lanschot, either by e-mail to proxyvoting@kempen.nl or by telefax +31 20 348 9549.

Prior to the EGM, the proxy holder shall hand in the admission ticket and a copy of the proxy instrument at the registration desk.

For further information, please contact Diego Mortillaro, at IGEA Pharma N.V., Siriusdreef 17, 2132 WT Hoofddorp, the Netherlands, or via e-mail at mortillaro@igearesearch.com.

I look forward to your participation on November 29, 2018.

Yours sincerely,

On behalf of the Management Board,

Diego Mortillaro
Chief Executive Officer